Full Name
Ms Jill DeSimone RPh
Practice/Company Name
Northeastern University
Speaker Bio
Jill M. DeSimone
Jill DeSimone is a senior biopharmaceutical executive with a reputation for leading large-scale global business transformations that revitalize Fortune 500 companies and revolutionize patient care with innovative, cutting-edge therapies. She brings award-winning leadership (2021 MM&M Hall of Femme) and a record of turning declining businesses into top-ranked performers and market leaders.
Jill builds innovative, high-performing organizations with cultures of trust and accountability that drive patient and customer impact. She establishes excellence in commercial and patient-centric operations while influencing Board and C-suite decisions to ignite profitable, scalable growth and enable agility in complex regulatory environments and dynamic, competitive markets.
Before retiring in March 2022 from her role as President, U.S. Oncology at Merck, Jill accelerated the transition from a legacy primary care company to a specialty business by creating and launching the U.S. Oncology business. She transformed a $500MM division with a declining oncology portfolio into a $10BN+ enterprise with one of the largest and fastest growing products in the history of the pharmaceutical industry.
Jill currently sits on the boards of Affini-T Therapeutics, a biotechnology company unlocking the power of T cells against oncogenic driver mutations; Praxis Precision Medicines, a biotech company developing experimental new medicine for patients and families impacted by mutations in the SNC2A gene; and the Florida Cancer Specialist Foundation, a nonprofit organization that delivers non-medical aid to individuals undergoing treatment for cancer. She holds a Bachelor’s degree in Pharmacy from Northeastern University and completed a fellowship with The Wharton School.
(609) 712-0265 | jilldesimone@hotmail.com | linkedin.com/in/jill-desimone
Jill
Jill DeSimone is a senior biopharmaceutical executive with a reputation for leading large-scale global business transformations that revitalize Fortune 500 companies and revolutionize patient care with innovative, cutting-edge therapies. She brings award-winning leadership (2021 MM&M Hall of Femme) and a record of turning declining businesses into top-ranked performers and market leaders.
Jill builds innovative, high-performing organizations with cultures of trust and accountability that drive patient and customer impact. She establishes excellence in commercial and patient-centric operations while influencing Board and C-suite decisions to ignite profitable, scalable growth and enable agility in complex regulatory environments and dynamic, competitive markets.
Before retiring in March 2022 from her role as President, U.S. Oncology at Merck, Jill accelerated the transition from a legacy primary care company to a specialty business by creating and launching the U.S. Oncology business. She transformed a $500MM division with a declining oncology portfolio into a $10BN+ enterprise with one of the largest and fastest growing products in the history of the pharmaceutical industry.
Jill currently sits on the boards of Affini-T Therapeutics, a biotechnology company unlocking the power of T cells against oncogenic driver mutations; Praxis Precision Medicines, a biotech company developing experimental new medicine for patients and families impacted by mutations in the SNC2A gene; and the Florida Cancer Specialist Foundation, a nonprofit organization that delivers non-medical aid to individuals undergoing treatment for cancer. She holds a Bachelor’s degree in Pharmacy from Northeastern University and completed a fellowship with The Wharton School.
(609) 712-0265 | jilldesimone@hotmail.com | linkedin.com/in/jill-desimone
Jill
Speaking At
